RecruitingPhase 4NCT02621645

TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence

Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy


Sponsor

Universitaire Ziekenhuizen KU Leuven

Enrollment

126 participants

Start Date

May 1, 2016

Study Type

INTERVENTIONAL

Conditions

Summary

Multi-center open-label randomized controlled trial to assess if early intervention (12.0-14.0 weeks) (study group) improves the outcome of TRAP sequence as compared to late intervention (16.0-19.0 weeks) (control group). The investigators will randomly assign women diagnosed with TRAP sequence diagnosed between 12.0 and 13.6 weeks to an early or late intervention group (1:1), using a web-based application and a computer-generated list with random permuted blocks of sizes 2 or 4 (www.sealedenvelope.com), stratified by gestational age (GA) at inclusion (11.6 -12.6 weeks versus 13.0-13.6 weeks). Analysis will be by intention to treat.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

  • TRAP sequence in a monochorionic diamniotic twin pregnancy diagnosed between 11.6 and 13.6 weeks, as determined by the crown-rump length of the pump twin in spontaneous conceptions and by the date of insemination or embryonic age at replacement in pregnancies resulting from subfertility treatment
  • Women aged 18 years or more, who are able to consent
  • Anatomically normal pump twin
  • Provide written informed consent to participate in this randomized controlled trial, forms being approved by the Ethical Committees

Exclusion Criteria4

  • Contraindication for an intervention due to a severe maternal medical condition or threatening miscarriage
  • Inaccessibility of the acardiac twin due to a retroverted uterus, severe maternal obesity, uterine fibroids, bowel or placental superposition
  • A major anomaly in the pump twin, requiring surgery or leading to infant death or severe handicap
  • Spontaneous arrest of the reverse flow and/or pump twin demise at diagnosis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREEarly selective reduction of TRAP mass

Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle

PROCEDURELate selective reduction of TRAP mass

Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.

DEVICEUltrasound-guided intrafetal ablation using a 18 to 20 Gauge needle
DEVICEUltrasound-guided intrafetal ablation using a 17 to 20 Gauge needle
DEVICELaser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber

Locations(14)

Children's Memorial Hermann Hospital

Houston, Texas, United States

Universitätsklinik für Frauenheilkunde und Geburtshilfe

Graz, Austria

Universitaire Ziekenhuizen Leuven

Leuven, Belgium

Mount Sinai Hospital

Toronto, Canada

Centre Médico-Chirurgical et Obstétrical

Schiltigheim, France

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany

Sheba Medical Center

Tel Litwinsky, Israel

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Milan, Italy

Ospedale dei Bambini Vittore Buzzi

Milan, Italy

Leiden University Medical Center

Leiden, Netherlands

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Birmingham Women's Hospital

Birmingham, United Kingdom

King's College

London, United Kingdom

St. George's Hospital, University of London (UK sponsor)

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02621645


Related Trials